Quinazoline-urea, new protein kinase inhibitors in treatment of prostate cancer.

Antonio Garofalo, Laurence Goossens, Amelie Lemoine, Amaury Farce, Yannick Arlot, Patrick Depreux

Index: J. Enzyme Inhib. Med. Chem. 25(2) , 158-71, (2010)

Full Text: HTML

Abstract

Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor-2 (VEGFR-2), two protein tyrosine kinases, are involved in pathological disorders and the progression of different types of carcinomas. Concomitant inhibition of both tyrosine kinase activities appears to be an attractive target for cancer chemotherapy. A series of new quinazoline derivatives substituted by amide, urea, or carbamic acid ester groups have been synthesized. The biological activities of these new compounds have been evaluated for their enzyme inhibition and antiproliferative activities.